Lizzul Paul F. — SEC insider filings
SEC reporting owner CIK 1711462. 25 insider filings on record with FilingPulse; latest filed 2026-11-03.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2021-02-12 to 2026-11-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 10 filings — 23,483 shares, $895,164 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 57.
- Largest priced transaction: sale of 4,219 shares @ $43.26 ($182,514) in ANAPTYSBIO, INC, filed 2026-01-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | Chief Medical Officer | 20 | — | 10 legs · 23,483 sh · $895,164 | 41 |
| First Tracks Biotherapeutics, Inc. (TRAX) | Chief Medical Officer | 5 | — | — | 16 |
Insider filings — Lizzul Paul F.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-03 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 42,500 (derivative) @ $0 | EDGAR |
| 2026-08-18 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 60,492 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 60,492 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 72,300 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 83,500 (derivative) @ $0 · Grant/award (A): 45,000 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0 · Grant/award (A): 67,070 (derivative) @ $0 · Grant/award (A): 115,540 (derivative) @ $0 · Grant/award (A): 97,200 (derivative) @ $0 · +5 more | EDGAR |
| 2026-01-09 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 8,525 · Sale (S): 3,650 @ $44.71 · Option exercise (M): 8,525 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 6,145 · Sale (S): 2,235 @ $45.11 · Option exercise (M): 6,145 (derivative) @ $0 · Grant/award (A): 21,400 (derivative) @ $0 · Grant/award (A): 29,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 10,555 · Sale (S): 4,219 @ $43.26 · Option exercise (M): 10,555 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 1,500 @ $18.50 · Sale (S): 1,500 @ $50 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 10,555 · Tax withholding (F): 4,336 @ $14.60 · Option exercise (M): 6,145 · Tax withholding (F): 2,261 @ $15.30 · Option exercise (M): 10,555 (derivative) @ $0 · Option exercise (M): 6,145 (derivative) @ $0 · +2 more | EDGAR |
| 2024-09-24 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 1,500 @ $18.50 · Sale (S): 1,500 @ $38.67 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2024-09-17 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 6,000 · Sale (S): 2,220 @ $38.93 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2024-08-16 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 2,000 @ $18.50 · Sale (S): 2,000 @ $40 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2024-07-24 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-07-19 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 1,500 @ $18.50 · Sale (S): 1,500 @ $35 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2024-01-09 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 6,145 @ $0 · Sale (S): 2,554 @ $21.81 · Option exercise (M): 6,145 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 115,540 (derivative) @ $0 · Grant/award (A): 42,220 (derivative) @ $0 | EDGAR |
| 2023-09-18 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 6,000 · Sale (S): 2,105 @ $19.48 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2023-01-10 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 67,070 (derivative) @ $0 · Grant/award (A): 24,580 (derivative) @ $0 | EDGAR |
| 2022-09-16 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2021-11-17 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 964 @ $22.03 | EDGAR |
| 2021-02-12 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-02-12 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1711462 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs